Safety control of switchable chimeric antigen receptor T cells using dose-adjustable adapters
A switchable CAR-T cell system using peptide tags and specific antibodies addresses the toxicity issues of conventional CAR-T cells by controlling activation and reducing off-tumor effects, effectively targeting cancer cells.
JP2026518706APending Publication Date: 2026-06-09SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION +1
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
- Filing Date
- 2024-05-20
- Publication Date
- 2026-06-09
Smart Images
Figure 2026518706000001_ABST
Abstract
Chimeric antigen receptor transducers (CAR-T cells) exhibit outstanding efficacy against certain hematological malignancies. However, CAR targets are limited to a small number of antigens, primarily due to the intra-target extratumor toxicity of CAR-T cells. Several strategies have been proposed to circumvent this intra-target extratumor toxicity, but most utilize complex designs, including dual gene expression for specificity. In this study, we demonstrate that switchable CAR immune cells (e.g., CAR-T cells) with tumor targeting adapters can mitigate intra-target extratumor toxicity against tumor antigens that could not be targeted by existing CAR immune cells due to toxicity, such as CD40 and CS1. Therefore, switchable CAR systems are a valuable tool for controlling CAR-T cell toxicity while maintaining therapeutic efficacy, enabling the expansion of CAR antitumor targeting.
Need to check novelty before this filing date? Find Prior Art